



The difference between the proportion of prescriptions due to the introduction of the financial incentives (solid line) and counterfactual (dashed line) represents the beta estimate of the financial incentive (average treatment effect in the treatment group: ATT).

The financial incentives were associated with a significant increase in the proportion of biosimilar product prescriptions, with a monthly increase of 0.092 per month (95% CI, 0.040–0.145) [9.2%, 95% CI, 4.0–14.5]

← April 2022

Itoshima H, Takada D, Goto E, Sasaki N, Kunisawa S, Imanaka Y. The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data. PLoS One. 2024;19(11):e0312577.

The financial incentive to promote the use of biosimilar products was introduced in April 2022 (corresponding to 0 on the X-axis).